ArticleTherapeutic delivery2025
Insight on the biomimetic of lysozyme interaction with functionalized iron oxide nanoparticles.
Article in Therapeutic delivery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionLysozyme is a globular hydrolytic enzyme whose tissue level is imperative for various clinical diagnostics. High levels of lysozyme are related to several inflammatory disorders, that breakdown cartilaginous tissues. Recently nanostructures have become widely used as modulators for enzyme activity. AREAS COVERED: This study delves into the influential role played by surface-modified iron oxide nanoparticles (IONPs) as novel lysozyme nano-inhibitors. Stern-Volmer plots results for lysozyme interaction with Cit-IONPs and Thy-IONPs reveal dynamic quenching constant (KSV) of 40.075 and 65.714 ml/mg, binding constant (Kb) of 1.539 × 103 and 4.418 × 103 ml/mg, and binding free energy (∆G°binding) of -43.563 KJ. mol EXPERT OPINION/COMMENTARY: Both formulations of IONPs demonstrate high affinity toward lysozyme proteins. This work shows a higher binding affinity between lysozyme and Thy-IONPs than with Cit-IONPs. These findings suggest that Thy-IONPs represent a promising class of nano-inhibitors for lysozyme, opening new avenues for treating disorders associated with lysozyme overexpression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.